Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAB001 in Knee Osteoarthritis
NCT07652372Phase 1Enrolling by invitation
- Sponsor
- Zhongshan Laibo Ruichen Biopharmaceutical
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LLP2A-alendronate in knee osteoarthritis (OA) (5 arms), sponsored by Zhongshan Laibo Ruichen Biopharmaceutical. Primary endpoints: Western Ontario and McMaster Universities Osteoarthritis Index Item A1 (walking pain) at 24 weeks, Western Ontario and McMaster Universities Osteoarthritis Index Scale A (Pain) at 24 weeks and 10 more. Started Apr 2026; status: enrolling by invitation.
02
Drugs
LLP2A-alendronate
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07652372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652372.